BIOMARKER OF CLINICAL DIAGNOSIS AND THERAPEUTIC MANAGEMENT OF SUBCLINICAL MASTITIS IN COW

Abstract

The timing of mastitis and sub-clinical mastitis outbreaks often gives important clues to the origin of herd problems. Infection rates are highest before calving, during early lactation, and near dry-off. The goal of every dairy farmer should be to minimize the number of organisms permitted to come into contact with the teats. To simplify the understanding of mastitis complexity, it is useful to detect the severity of the disease as well as diagnosis and therapeutic strategies. Serum amyloid A and haptoglobin are the two major acute-phase proteins and fibrinogen is a minor acute-phase protein in cattle. The therapeutic experiment was conducted by using four groups including Group A animals treated with only Bovimint, Group B animals with Bovimint + Mastotreet, and Group C with Bovimint + Mastotreet + Inj. Enrofloxacin, and Group D with Bovimint + Inj. Enrofloxacin. They are potentially useful as disease markers owing to their low concentration in normal animals, the rapid increase in their concentration during the acute phase of inflammation, and their rapid decrease with the resolution of the disease. To minimize economic losses due to high prevalence, its early detection with suitable tests and appropriate treatment regimen becomes most important. From the study, it was observed that treatment with Bovimint and Inj Enrofloxacin depicted the best recovery of the other treatment groups. Effective antimicrobial coverage along with local application on the udder would be a more suitable regimen of treatment against sub-clinical mastitis.

Keywords

• sub clinical mastitis
• biomarker
• clinical diagnosis
• treatment